ADMA Biologics Inc (ADMA) was Downgraded by Raymond James to ” Mkt Perform”. Earlier the firm had a rating of “Strong Buy ” on the company shares. Raymond James advised their investors in a research report released on Aug 1, 2016.
Many Wall Street Analysts have commented on ADMA Biologics Inc. Shares were Reiterated by Maxim Group on Jul 25, 2016 to “Buy” and Lowered the Price Target to $ 14 from a previous price target of $24 .
ADMA Biologics Inc opened for trading at $7.4415 and hit $8 on the upside on Friday, eventually ending the session at $7.85, with a gain of 7.39% or 0.54 points. The heightened volatility saw the trading volume jump to 97,947 shares. Company has a market cap of $101 M.
In a different news, on May 5, 2016, James Mond (CSO/CMO) purchased 770 shares at $6.50 per share price. According to the SEC, on May 5, 2016, Brian Lenz (CFO) purchased 2,500 shares at $6.50 per share price. On May 5, 2016, Adam S Grossman (CEO) purchased 200,000 shares at $6.50 per share price, according to the Form-4 filing with the securities and exchange commission.
ADMA Biologics Inc. is a biopharmaceutical company that develops and manufactures specialty plasma-based biologics for the treatment and prevention of certain infectious diseases. The company’s targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. The Company’s lead product candidate RI-002 is intended for the treatment of primary immune deficiency disease (PIDD). RI-002 is an injectable immune globulin derived from human plasma with levels of naturally occurring polyclonal antibodies as well as levels of antibodies targeted to respiratory syncytial virus (RSV). The company’s RI-002 demonstrated Phase III results and attained its primary endpoint and preliminary analysis indicates that the treatment with RI-002 resulted in no serious bacterial infections (SBI’s) observed in study subjects during the trial.